



Dear Valued Client,

National Jewish Health Advanced Diagnostic Laboratories is proud to introduce a [targeted next-generation sequencing \(tNGS\)](#) assay, primarily for *Mycobacterium tuberculosis* complex (MTBC). Utilizing a molecular methodology, tNGS dramatically reduces the time needed to identify TB directly from sputum and simultaneously assesses resistance to 13 anti-tuberculosis drugs.

Testing can be performed on isolates as well as sputum samples. Tuberculosis identification will not be performed on sputum samples if the suspected organism is not MTBC.

The list of drugs that will be used for tNGS resistance testing:


- Rifampin
- Isoniazid
- Pyrazinamide
- Ethambutol
- Ethionamide
- Streptomycin
- Fluoroquinolones
- Kanamycin
- Amikacin
- Capreomycin
- Linezolid

- Clofazimine
- Bedaquiline.

For more details about the test, see our test catalog page here: <https://www.nationaljewish.org/for-professionals/diagnostic-testing/advanced-diagnostic-laboratories/targeted-next-gen-sequencing-for-mycobacteria>

If you have any questions about this new test, please contact our Client Services team at 800.550.6227 or via email at ClinRefLabs@NJHealth.org.

Sincerely,



Steve Groshong, MD, PhD
Medical Director, Advanced Diagnostic Laboratories
National Jewish Health

njlabs.org | 800.550.6227 (toll-free) | 800.652.9556 (fax)

[Unsubscribe](#) from emails from this list.